Published Guideline
READ GUIDELINE
Updated Content (last reviewed 2/10/25)
In accordance with the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines, SITC CPGs undergo periodic evaluation to assess if new evidence necessitates modifications to recommendations, treatment algorithms, or other guideline content. This is done through our “SITC Living Guidelines” rapid update protocols designed to ensure SITC CPGs are up-to-date with cutting-edge thinking and incorporate the leading expert guidance in cancer immunotherapy care – a vital service to treating clinicians and those along the whole cancer care continuum.
The information below provides an overview of the updates made to the "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma" since its publication in Journal for ImmunoTherapy of Cancer (JITC).
Rapid Update v1.4 Summary
- Based on the FDA approvals and practice-changing data listed below, updates have been made to the guideline's narrative text, recommendations, and Table 4.
- The FDA granted approval of denileukin diftitox-cxdl for the treatment of patients with stage 1 to 3 relapsed/refractory cutaneous TCL after at least 1 prior systemic therapy in August 2024.
- The FDA granted accelerated approval of epcoritamab for adult patients with relapsed or refractory FL after two or more lines of systemic therapy in June 2024.
- The FDA granted approval of lisocabtagene maraleucel for adult patients with relapsed or refractory mantle cell lymphoma MCL who have received at least two prior lines of systemic therapy, including a Bruton tyrosine kinase inhibitor (BTKi) in May 2024.
- The FDA granted accelerated approval of lisocabtagene maraleucel for adults with relapsed or refractory FL who have received two or more prior lines of systemic therapy in May 2024.
- The FDA granted accelerated approval of lisocabtagene maraleucel for adult patients with relapsed or refractory CLL or SLL who have received at least 2 prior lines of therapy, including a BTKi and a B-cell lymphoma 2 (BCL-2) inhibitor in March 2024.
- The FDA granted accelerated approval of zanubrutinib with obinutuzumab for relapsed or refractory FL after two or more lines of systemic therapy in March 2024.
- The FDA granted accelerated approval of glofitamab for relapsed or refractory diffuse large B-cell lymphoma DLBCL, not otherwise specified (NOS) or LBCL arising from FL, after two or more lines of systemic therapy in June 2023.
- The FDA granted accelerated approval of epcoritamab for relapsed or refractory DLBCL NOS, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma (HGBL) after two or more lines of systemic therapy in May 2023.
- The FDA granted approval of polatuzumab vedotin with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for adult patients who have previously untreated DLBCL, NOS or HGBL and who have an International Prognostic Index (IPI) score of 2 or greater in April 2023.
- The FDA granted accelerated approval of mosunetuzumab for adult patients with relapsed or refractory FL after two or more lines of systemic therapy in December 2022.
- Data have been reported on the safety and efficacy of lenalidomide + obinutuzumab for relapsed or refractory FL and marginal zone lymphoma.
- Data have been reported on the safety and efficacy of nivolumab + AVD for patients with Hodgkin lymphoma.
- Data have been reported on the safety and efficacy of nivolumab + chemotherapy and pembrolizumab + chemotherapy for patients with relapsed or refractory Hodgkin lymphoma.
- Data have been reported on the safety and efficacy of BV-nivolumab for the treatment of R/R PMBCL.
Rapid Update v1.3 Summary
- Based on the approval of axicabtagene ciloleucel for adult patients with large B-cell lymphoma (LBCL) that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy, the Lymphoma CPG has been updated in the "Available Agents and Indications for NHL" and "Expert Panel Recommendations for NHL" sections.
- Based on the approval of tisagenlecleucel for the treatment of adult patients with relapsed or refractory follicular lymphoma following 2 or more lines of systemic therapy, the Lymphoma CPG has been updated in the "Available Agents and Indications for NHL" section.
- Based on the approval of lisocabtagene maraleucel for the treatment of adult patients with large B-cell lymphoma (LBCL) who have refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy; or refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplantation (HSCT) due to comorbidities or age, the Lymphoma CPG has been updated in the "Available Agents and Indications for NHL" section.
Rapid Update v1.2 Summary
- Based on the approval of loncastuximab tesirine-lpyl for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low grade lymphoma, and high-grade B-cell lymphoma, the Lymphoma CPG has been updated in the "Available Agents and Indications for NHL" section.
Rapid Update v1.1 Summary
- Updates to narrative text and recommendations based on approval for axicabtagene ciloleucel for second-line treatment of LBCL.
- Update to narrative text based on approval of loncastuximab tesirine-lpyl.
- Update to narrative text based on approval of lisocabtagene maraleucel.
- Updates to the narrative text based on approval of tisagenlecleucel.